Navigation Links
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
Date:5/15/2012

ive, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill™, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

*Note: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

- Continued - Cardium Therapeutics, Inc.Selected Condensed Consolidated Results of OperationsAs of March 31
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium to Present at Upcoming Investor Conferences
2. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
5. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
6. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
7. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
8. Cardium Regains Listing Compliance With NYSE Amex
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
11. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... November 21, 2014 RURO, Inc., ... provider, has released Limfinity® version 5.1.4. , RURO’s ... of Limfinity® than ever in RURO’s 8 year ... minority framework enhancement. Limfinity® version 5.1.4 is the ... and beyond bug fixes! , Limfinity® 5.1.4 release ...
(Date:11/22/2014)... 2014 The “Chiral Chromatography Columns ... Material (Metal, Glass, Plastic), by Application [GC, LC ... Forecast to 2018” analyses and studies the major ... America, Europe, Asia, and Rest of the World. ... figures spread through 135 pages and in-depth TOC ...
(Date:11/22/2014)... 2014  The element of surprise has been a ... strike without warning. Until now, epidemiologists had nothing to ... outbreak, resulting in suboptimal responses to both the H1N1 ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... because virus gene structural changes have been found that ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5Viruses' Advantage of Surprise is Lost 2
... Viruses can wreak havoc on bacteria as well as humans ... in place, explains Professor John van der Oost, at the ... the bacterial "immune system" could be used to keep industrial ... his team at Wageningen University in the Netherlands have spent ...
... ... statistically significant pain relief at five minutes post-dose using electronic patient diary data ... PITTSBURGH, PA (Vocus) ... outcomes (PRO) solutions and services for global clinical research, today announced that its ...
... immune system senses and tracks down infection in the body ... immune cells manipulate their movement in response to external signals ... functions but also how cancer cells spread through the body ... the Society for General Microbiology,s spring meeting in Edinburgh, Dr ...
Cached Biology Technology:invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial 2invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial 3How immune cells 'sniff out' bacteria 2
(Date:11/4/2014)... – University of Utah engineers developed the first room-temperature ... produce electricity without needing to ignite the fuel. These ... electronics, off-grid power and sensors. , A study of ... Chemical Society journal ACS Catalysis . , Fuel ... between a fuel and an oxygen-rich source such as ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/3/2014)... ANGELES , Nov. 3, 2014  NeuroSigma ... -based life sciences company focused on commercialization ... system for the treatment of neurological and ... of Industrial Property has issued a Notice of ... patent application is co-owned by NeuroSigma and the ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Researchers at Brigham and Women,s Hospital (BWH) have demonstrated ... human platelet function and causes a peak in platelet ... cardiovascular events. These findings are published in PLoS ... disease is still the number one cause of death ...
... article (DOI: 10.1603/IPM10024) in the Journal of Integrated ... species of thrips present in U.S. cotton, their plant host ... biology, and management practices currently available to growers. ... in the United States and constitute one of the most ...
... DC (Sept 9, 2011) -- The blood levels of ... patients will develop heart problems, need dialysis, and die ... issue of the Journal of the American Society ... which patients need early treatment, thereby lowering their health ...
Cached Biology News:Body clock found to regulate platelet function 2Hormone predicts which kidney patients might die early 2